Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.
The yet-to-be-published studies involve drugs in a new class designed to enable the body’s immune system to fight cancer.
Source: Reuters
Filed Under: Drug Discovery
